

### **Amendments to the Claims**

This listing of claims will replace all prior versions, and listings of claims in the application.

#### **Listing of Claims**

1. (Previously Presented) A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound consisting of the formula  $X_1$ -SEQ ID NO:1- $X_2$  wherein

$X_1$  is from zero to twelve amino acids, and

$X_2$  is from zero to twelve amino acids.

2. (Original) The composition of Claim 1, wherein

$X_1$  is from zero to six amino acids, and

$X_2$  is from zero to six amino acids

3. (Original) The composition of claim 1 wherein

$X_1$  is

(i) zero amino acids, or

(ii) the segment SEQ ID NO:2, or N-terminal truncation fragment thereof containing at least one amino acid, and

$X_2$  is

(i) zero amino acids, or

(ii) the segment SEQ ID NO:3, or C-terminal truncation fragment thereof containing at least one amino acid.

4. (Original) The composition of claim 1 wherein the compound has substantial amino acid sequence homology to the amino acid sequence SEQ ID NO:4.

5. (Original) The composition of claim 1 wherein the compound has the amino acid sequence SEQ ID NO:1.

6. (Original) The composition of claim 1 wherein the compound has the amino acid sequence SEQ ID NO:9.

7. (Original) The composition of claim 1 wherein the compound has the amino acid sequence SEQ ID NO:10.

8 Cancelled

9. Cancelled

10. Cancelled

11. Cancelled

12. Cancelled

13. Cancelled

14. Cancelled

15. Cancelled

16. Cancelled

17. Cancelled

18. Cancelled

19. Cancelled

20. Cancelled

21. Cancelled

22. Cancelled

23. Cancelled

24. (Original) A method of inhibiting angiogenesis comprising administering to a mammal an effective amount of a composition according to claim 1.

25. Cancelled

26. Cancelled

27. Cancelled

28. Cancelled

29. Cancelled

30. Cancelled

31. Cancelled
32. Cancelled
33. Cancelled
34. Cancelled
35. Cancelled
36. Cancelled
37. Cancelled
38. Cancelled
39. Cancelled
40. Cancelled
41. Cancelled
42. Cancelled
43. Cancelled
44. Cancelled
45. Cancelled
46. Cancelled
47. Cancelled
48. Cancelled

49. (Previously presented) A method of inhibiting angiogenesis comprising administering to a mammal effective amount of a composition according to claim 2.

50. (Previously presented) A method of inhibiting angiogenesis comprising administering to a mammal effective amount of a composition according to claim 3.

51. (Previously presented) A method of inhibiting angiogenesis comprising administering to a mammal effective amount of a composition according to claim 4.

52. (Previously presented) A method of inhibiting angiogenesis comprising administering to a mammal effective amount of a composition according to claim 5.

53. (Previously presented) A method of inhibiting angiogenesis comprising administering to a mammal effective amount of a composition according to claim 6.

54. (Previously presented) A method of inhibiting angiogenesis comprising administering to a mammal effective amount of a composition according to claim 7.

55. (Previously presented) A method for inhibiting angiogenesis comprising administering to a mammal an effective amount of a compound of the formula  $X_1$ -SEQ ID NO:1- $X_2$  wherein

$X_1$  is from zero to twelve amino acids, and

$X_2$  is from zero to twelve amino acids.

56. (Currently Amended) A method of inhibiting angiogenesis according to claim 1 ~~55~~ wherein

$X_1$  is

(i) zero amino acids, or

(ii) the segment SEQ ID NO:2, or N-terminal truncation fragment thereof containing at least one amino acid, and

$X_2$  is

(i) zero amino acids, or

(ii) the segment SEQ ID NO:3, or C-terminal truncation fragment thereof containing at least one amino acid.